ARA-290 (Cibinetide)

Mechanism

ARA-290 is an 11-amino-acid peptide engineered from the tissue-protective part of erythropoietin (EPO) — but without EPO's blood-thickening effects. It activates the innate repair receptor, which shifts the body's response from chronic inflammation toward tissue repair and regeneration. It has shown particularly promising results for nerve damage (neuropathy), including diabetic neuropathy and sarcoidosis-related small fiber neuropathy, where it helped regrow damaged nerve fibers.

Effects

NEUROLOGICAL: Primary clinical target — small fiber neuropathy. In RCTs: improved neuropathic and autonomic symptoms in sarcoidosis-associated small fiber neuropathy (SFN). Initiated corneal nerve fiber regrowth after 28 days of treatment — demonstrating actual nerve regeneration, not just symptom management (IOVS, 2017). Specifically inhibits TRPV1 channel activity, relieving mechanical hypersensitivity induced by capsaicin. Engages innate repair receptor on glia, supporting Schwann cell function and nerve repair. Reduces microglial activation and neuroinflammation. Potential applications: diabetic neuropathy, chemotherapy-induced neuropathy, post-herpetic neuralgia. IMMUNE: Anti-inflammatory pathway activation — shifts immune response from tissue damage toward tissue repair. Modulates T-cell behavior — reduces pro-inflammatory T-cell activation. Reduces monocyte and microglia activation. Does NOT stimulate erythropoiesis — critical distinction from EPO (no risk of polycythemia or thrombosis). CARDIOVASCULAR: Supports endothelial function and barrier integrity. Protects small vessels and reduces vascular leak — maintains nutrient and oxygen delivery to vulnerable axons. Improves vascular function in diabetic microvascular disease (Phase II data). METABOLIC: Improved metabolic control in type 2 diabetes patients — HbA1c reduction and improved insulin sensitivity observed in Phase II trial (Brines et al., 2015, PMID: 25369768). MUSCULOSKELETAL: No direct musculoskeletal effects, but pain relief from neuropathy improves functional capacity and mobility. ENDOCRINE: Improves insulin sensitivity (metabolic endocrine effect). SKIN: Protects and regenerates cutaneous nerve fibers — relevant for diabetic and inflammatory skin conditions. Tier 3: Growing practitioner interest for neuropathic pain conditions unresponsive to standard treatment. Some integrative neurologists have explored it in clinical practice.

Practitioner Guide

DOSING TIPS: Based on clinical trial protocols: 2-4 mg subcutaneous injection, administered daily or 3x/week. Phase II trials typically used 4 mg SC daily for 28 days. Start at 2 mg and titrate to 4 mg based on tolerance. Some practitioners use longer treatment courses (8-12 weeks) for established neuropathy. RECONSTITUTION: Lyophilized peptide — reconstitute with bacteriostatic water. For 10mg vial: add 2.5mL BAC water = 4mg/mL. Use insulin syringe for SubQ injection. INJECTION SITE: Subcutaneous — abdominal fat pad or thigh. No specific site preferences for neuropathy treatment. TIMING: Morning or evening — no specific timing advantage documented. Consistency matters more than timing. SUPPLEMENT SYNERGIES: Alpha-lipoic acid (600mg/day) — established for diabetic neuropathy, complementary mechanism. B-complex vitamins — especially B1 (benfotiamine 300mg/day), B6, B12 — support nerve health. Acetyl-L-carnitine (1000-2000mg/day) — supports peripheral nerve regeneration. Lion's Mane mushroom — promotes NGF production. Omega-3 fatty acids — anti-inflammatory, support nerve membrane integrity. CYCLING: Based on clinical trial design: 28-day treatment courses with reassessment. Some practitioners use continuous treatment for chronic neuropathy. May need multiple courses for nerve fiber regrowth (regeneration takes months). STACKING: Neuropathy: ARA-290 + BPC-157 + Alpha-lipoic acid + B-complex. Anti-inflammatory: ARA-290 + KPV + LL-37. Diabetic health: ARA-290 + Semaglutide + Berberine. CONTRAINDICATION NUANCES: Theoretically safe based on clinical trials, but not FDA-approved. Patients with EPO-dependent conditions (polycythemia vera) — ARA-290 does NOT activate erythropoiesis, so this should not be a concern, but monitor as a precaution. Patients on immunosuppressants — effects on immune modulation could interact. STORAGE: Lyophilized — refrigerate or store at -20°C. Reconstituted — refrigerate, use within 2-4 weeks. PATIENT EDUCATION: ARA-290 is derived from the tissue-repair part of erythropoietin (EPO) but does NOT affect your blood count or cause blood thickening. It specifically activates your body's innate repair system to heal damaged nerves. Clinical trials have shown actual nerve fiber regrowth — not just pain relief. Effects take 2-4 weeks to become noticeable. This is one of the more clinically advanced peptides, with multiple Phase II trials completed.

Evidence

• A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.

  Lois N, Gardner E, McFarland M, Armstrong D, McNally C, Lavery NJ, Campbell C, Kirk RI, Bajorunas D, Dunne A, Cerami A, Brines M (2020) — Journal of Clinical Medicine — PMID: 32674280

  In a 12-week phase 2 study of cibinetide 4 mg/day in diabetic macular edema, eight of nine enrolled patients completed treatment with no serious adverse events or anti-drug antibodies. Mean visual acuity and retinal thickness did not improve overall, but some participants showed favorable shifts in retinal thickness, tear production, glycemic control, and albuminuria, supporting a safe but still exploratory efficacy profile.

  emerging

• ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

  Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M (2013) — Molecular Medicine — PMID: 24136731

  In a 28-day blinded placebo-controlled trial in patients with sarcoidosis-associated small fiber neuropathy, daily subcutaneous ARA-290 significantly improved neuropathic symptoms, increased corneal small nerve fiber density, shifted thermal pain thresholds, and improved 6-minute walk performance. Findings support cibinetide/ARA-290 as a regenerative anti-inflammatory candidate for neuropathic sarcoid symptoms, while remaining limited by short duration and narrow indication.

  moderate

Research Summary

TIER 1 (Gold Standard): Brines et al., 2015 — ARA 290 improves metabolic control and neuropathic symptoms in T2D (PMID: 25369768, Phase II RCT). Dahan et al., 2013 — Safety and efficacy of ARA 290 in sarcoidosis patients with SFN (RCT, Molecular Medicine). Brines & Cerami, 2012 — targeting the innate repair receptor (PAIN Reports, review). TIER 2 (Strong): Ceravolo et al., 2017 — Cibinetide improves corneal nerve fiber abundance in sarcoidosis-associated SFN (IOVS/ARVO). ARA 290 relieves pathophysiological pain by targeting TRPV1 channel (ScienceDirect, 2016). Brines et al. — multiple publications characterizing the innate repair receptor mechanism. Araim Pharmaceuticals pipeline documentation. TIER 3 (Moderate): Practitioner protocols for neuropathic pain. Case reports of use in various neuropathic conditions. Community reports of pain improvement. KEY FINDINGS: (1) ARA-290 has genuine Phase II clinical data — more clinical evidence than most research peptides. (2) Nerve fiber regrowth is a remarkable finding (not just symptom management). (3) The innate repair receptor mechanism is novel and well-characterized. (4) Non-erythropoietic — critical safety advantage over EPO. (5) Multiple indications (neuropathy, metabolic, vascular). GAPS: Phase III trials needed. Long-term nerve regeneration outcomes. Optimal treatment duration. Pediatric safety. ACTIVE TRIALS: Check ClinicalTrials.gov for current Araim Pharmaceuticals studies.